Abstract
Introduction: Bladder urothelial carcinoma is highly heterogeneous and is prone to recurrence. There are many types of drugs for intravesical instillation, and there is an urgent need for reliable tumor models for individualized treatment strategies. Patient-derived organoids (PDOs) are efficient and accurate neotype tumor models that can compensate for the deficiencies of traditional tumor models. Methods: From September 2023 to February 2024, bladder cancer tissues were collected from surgical resections in the Department of Urology, Beijing Tiantan Hospital, Capital Medical University. We explored suitable culture systems and cultured primary tumor cells in Matrigel matrix gels. Hematoxylin and eosin (HE) staining and immunohistochemistry were performed for comparison with the original tumor tissue at the histological level for validation. Drug sensitivity tests were also conducted. Results: In this study, a culture system for PDOs was successfully established. HE staining and immunohistochemistry were used to morphologically verify the organ model. Drug sensitivity tests have clarified the value of PDOs as preclinical models of precision medicine. Conclusion: A bladder tumor PDO culture platform was initially established, which laid a foundation for the subsequent construction of the organoid bank, the study of bladder tumor progression mechanism, and research in precision medicine.
Journal Section:
Research Article
References
1.
Sung
H
, Ferlay
J
, Siegel
RL
, Laversanne
M
, Soerjomataram
I
, Jemal
A
, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
. CA Cancer J Clin
. 2021
;71
(3
):209
–49
. 2.
Lopez-Beltran
A
, Cookson
MS
, Guercio
BJ
, Cheng
L
. Advances in diagnosis and treatment of bladder cancer
. BMJ
. 2024
;384
:e076743
. 3.
Babjuk
M
, Burger
M
, Capoun
O
, Cohen
D
, Comperat
EM
, Dominguez Escrig
JL
, et al. European association of Urology guidelines on non-muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ)
. Eur Urol
. 2022
;81
(1
):75
–94
. 4.
Alfred Witjes
J
, Max Bruins
H
, Carrion
A
, Cathomas
R
, Comperat
E
, Efstathiou
JA
, et al. European association of Urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2023 guidelines
. Eur Urol
. 2024
;85
(1
):17
–31
. 5.
Patel
VG
, Oh
WK
, Galsky
MD
. Treatment of muscle-invasive and advanced bladder cancer in 2020
. CA Cancer J Clin
. 2020
;70
(5
):404
–23
. 6.
Flaig
TW
, Spiess
PE
, Abern
M
, Agarwal
N
, Bangs
R
, Buyyounouski
MK
, et al. NCCN Guidelines® insights: bladder cancer, version 3.2024
. J Natl Compr Canc Netw
. 2024
;22
(4
):216
–25
. 7.
Caponigro
G
, Sellers
WR
. Advances in the preclinical testing of cancer therapeutic hypotheses
. Nat Rev Drug Discov
. 2011
;10
(3
):179
–87
. 8.
Imamura
Y
, Mukohara
T
, Shimono
Y
, Funakoshi
Y
, Chayahara
N
, Toyoda
M
, et al. Comparison of 2D- and 3D-culture models as drug-testing platforms in breast cancer
. Oncol Rep
. 2015
;33
(4
):1837
–43
. 9.
Whittle
JR
, Lewis
MT
, Lindeman
GJ
, Visvader
JE
. Patient-derived xenograft models of breast cancer and their predictive power
. Breast Cancer Res
. 2015
;17
(1
):17
. 10.
Jameson
SC
, Masopust
D
. What is the predictive value of animal models for vaccine efficacy in humans? Reevaluating the potential of mouse models for the human immune system
. Cold Spring Harb Perspect Biol
. 2018
;10
(4
):a029132
. 11.
Boretto
M
, Maenhoudt
N
, Luo
X
, Hennes
A
, Boeckx
B
, Bui
B
, et al. Patient-derived organoids from endometrial disease capture clinical heterogeneity and are amenable to drug screening
. Nat Cel Biol
. 2019
;21
(8
):1041
–51
. 12.
Mullenders
J
, de Jongh
E
, Brousali
A
, Roosen
M
, Blom
JPA
, Begthel
H
, et al. Mouse and human urothelial cancer organoids: a tool for bladder cancer research
. Proc Natl Acad Sci U S A
. 2019
;116
(10
):4567
–74
. 13.
Clevers
H
. Modeling development and disease with organoids
. Cell
. 2016
;165
(7
):1586
–97
. 14.
Dye
BR
, Hill
DR
, Ferguson
MA
, Tsai
YH
, Nagy
MS
, Dyal
R
, et al. In vitro generation of human pluripotent stem cell derived lung organoids
. Elife
. 2015
;4
:e05098
. 15.
Rock
JR
, Onaitis
MW
, Rawlins
EL
, Lu
Y
, Clark
CP
, Xue
Y
, et al. Basal cells as stem cells of the mouse trachea and human airway epithelium
. Proc Natl Acad Sci U S A
. 2009
;106
(31
):12771
–5
. 16.
Lancaster
MA
, Renner
M
, Martin
CA
, Wenzel
D
, Bicknell
LS
, Hurles
ME
, et al. Cerebral organoids model human brain development and microcephaly
. Nature
. 2013
;501
(7467
):373
–9
. 17.
McCracken
KW
, Cata
EM
, Crawford
CM
, Sinagoga
KL
, Schumacher
M
, Rockich
BE
, et al. Modelling human development and disease in pluripotent stem-cell-derived gastric organoids
. Nature
. 2014
;516
(7531
):400
–4
. 18.
Huch
M
, Dorrell
C
, Boj
SF
, van Es
JH
, Li
VS
, van de Wetering
M
, et al. In vitro expansion of single Lgr5+ liver stem cells induced by Wnt-driven regeneration
. Nature
. 2013
;494
(7436
):247
–50
. 19.
Boj
SF
, Hwang
CI
, Baker
LA
, Chio
II
, Engle
DD
, Corbo
V
, et al. Organoid models of human and mouse ductal pancreatic cancer
. Cell
. 2015
;160
(1–2
):324
–38
. 20.
Plaks
V
, Brenot
A
, Lawson
DA
, Linnemann
JR
, Van Kappel
EC
, Wong
KC
, et al. Lgr5-expressing cells are sufficient and necessary for postnatal mammary gland organogenesis
. Cell Rep
. 2013
;3
(1
):70
–8
. 21.
Sato
T
, Stange
DE
, Ferrante
M
, Vries
RG
, Van Es
JH
, Van den Brink
S
, et al. Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett's epithelium
. Gastroenterology
. 2011
;141
(5
):1762
–72
. 22.
van de Wetering
M
, Francies
HE
, Francis
JM
, Bounova
G
, Iorio
F
, Pronk
A
, et al. Prospective derivation of a living organoid biobank of colorectal cancer patients
. Cell
. 2015
;161
(4
):933
–45
. 23.
Minoli
M
, Cantore
T
, Hanhart
D
, Kiener
M
, Fedrizzi
T
, La Manna
F
, et al. Bladder cancer organoids as a functional system to model different disease stages and therapy response
. Nat Commun
. 2023
;14
(1
):2214
. 24.
Sachs
N
, de Ligt
J
, Kopper
O
, Gogola
E
, Bounova
G
, Weeber
F
, et al. A living biobank of breast cancer organoids captures disease heterogeneity
. Cell
. 2018
;172
(1–2
):373
–86.e10
. 25.
Li
X
, Fu
G
, Zhang
L
, Guan
R
, Tang
P
, Zhang
J
, et al. Assay establishment and validation of a high-throughput organoid-based drug screening platform
. Stem Cell Res Ther
. 2022
;13
(1
):219
. 26.
Wu
W
, Li
X
, Yu
S
. Patient-derived tumour organoids: a bridge between cancer biology and personalised therapy
. Acta Biomater
. 2022
;146
:23
–36
. 27.
Xu
H
, Jiao
D
, Liu
A
, Wu
K
. Tumor organoids: applications in cancer modeling and potentials in precision medicine
. J Hematol Oncol
. 2022
;15
(1
):58
. 28.
Wood
LD
, Ewald
AJ
. Organoids in cancer research: a review for pathologist-scientists
. J Pathol
. 2021
;254
(4
):395
–404
. 29.
Neal
JT
, Li
X
, Zhu
J
, Giangarra
V
, Grzeskowiak
CL
, Ju
J
, et al. Organoid modeling of the tumor immune microenvironment
. Cell
. 2018
;175
(7
):1972
–88.e16
. 30.
Achberger
K
, Probst
C
, Haderspeck
J
, Bolz
S
, Rogal
J
, Chuchuy
J
, et al. Merging organoid and organ-on-a-chip technology to generate complex multi-layer tissue models in a human retina-on-a-chip platform
. Elife
. 2019
;8
:e46188
. 31.
Fujii
M
, Shimokawa
M
, Date
S
, Takano
A
, Matano
M
, Nanki
K
, et al. A colorectal tumor organoid library demonstrates progressive loss of niche factor requirements during tumorigenesis
. Cell Stem Cell
. 2016
;18
(6
):827
–38
. 32.
Dekkers
JF
, Alieva
M
, Wellens
LM
, Ariese
HCR
, Jamieson
PR
, Vonk
AM
, et al. High-resolution 3D imaging of fixed and cleared organoids
. Nat Protoc
. 2019
;14
(6
):1756
–71
. 33.
Radic
M
, Egger
M
, Kruithof-de Julio
M
, Seiler
R
. Patient-derived organoids in bladder cancer: opportunities and challenges
. Eur Urol Focus
. 2024
. 34.
Dijkstra
KK
, Cattaneo
CM
, Weeber
F
, Chalabi
M
, van de Haar
J
, Fanchi
LF
, et al. Generation of tumor-reactive T cells by Co-culture of peripheral blood lymphocytes and tumor organoids
. Cell
. 2018
;174
(6
):1586
–98.e12
. © 2025 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2025
You do not currently have access to this content.
